Business Context and Reporting Period
Company: Dyadic International, Inc. (DYAI)
Filing Type: Form 8-K (Current Report)
Date of Report: December 19, 2025
Reporting Period: Event date December 19, 2025; Signed December 23, 2025
Business Overview: The Company is a Delaware corporation focused on microbial protein production platforms and related technologies, with principal executive offices in Jupiter, FL.
Key Financial Metrics
This filing is a notice of a listing deficiency and does not contain specific financial statements, revenue, profit, cash flow, margin, debt, or liquidity data for the current period. The filing text does not provide a clear value for these metrics.
Material Changes and Listing Status
- Deficiency Notice: On December 19, 2025, the Company received a notice from Nasdaq stating its common stock failed to maintain the minimum bid price of $1.00 per share for the last 30 consecutive business days (Nasdaq Listing Rule 5550(a)(2)).
- Immediate Effect: The notice has no immediate effect on the listing of the Company's common stock on the Nasdaq Capital Market.
- Compliance Timeline: The Company has 180 calendar days, until June 17, 2026, to regain compliance.
- Compliance Requirement: The stock must close at $1.00 per share or more for a minimum of 10 consecutive business days prior to the Compliance Date.
- Secondary Compliance Period: If the Company fails to comply by June 17, 2026, it may be eligible for an additional 180-day period if it meets the market value of publicly held shares requirement and other initial listing standards (except bid price) and provides written notice of intent to cure.
Outlook, Risks, and Management Commentary
Management Plan: The Company intends to actively monitor the bid price and evaluate available options to resolve the deficiency and regain compliance.
Risks and Contingencies:
- Delisting Risk: If the Company cannot cure the deficiency or is ineligible for a second compliance period, Nasdaq may issue a delisting notice. There is no assurance that an appeal to a hearings panel would be successful.
- Forward-Looking Risks: The filing highlights risks including a history of net losses, capital needs, ability to maintain other listing standards, market acceptance of microbial protein technologies, competition, clinical trial results, and reliance on third parties.
Investor Verification Checklist
- Verify the current trading price of DYAI to assess the gap from the $1.00 minimum bid requirement.
- Review the Company's most recent Form 10-K and 10-Q filings to confirm the "history of net losses" and current capital position.
- Monitor the Company's public announcements for any stock split or reverse stock split proposals intended to address the bid price deficiency.
- Check for any subsequent filings regarding the Company's intent to utilize the second 180-day compliance period if the initial deadline is missed.
- Assess the Company's progress on commercializing microbial protein production platforms as a driver for future valuation.